AstraZeneca’s research turnaround is unique in global drug history. What is the secret sauce?
I became chairman in 2012 and decided to replenish the pipeline. So, we hired Pascal Soriot (the company’s Executive Director and Chief Executive Officer). He and his team have done a much better evaluation of the projects we have. He not only brought discipline in the process, but also sharp decision making, and unsentimental decisions on which projects have to go. If there’s an element of risk or failure, then try to fail fast. By doing that, you free up resources for projects that we are standing behind.
In 2012, we spent almost 90 per cent of our R&D internally. Now, overall, what we are doing in our R&D with small or medium-sized companies, if you add transactions by molecules selling projects ( joint molecule development projects), then the number is probably 50-50. So, a combination of much better decision-making and opening up has meant four-fold productivity of new drug discovery. That is the remarkable effect Pascal Soriot’s team has had on the group.
What has been your experience in drug research costs? How do you optimise costs? What’s your experience spending dollars internally and working with other partners, including Sun Pharma in India?
The cost of making a drug is always increasing. The way to offset that is to try to fail fast. The trick is to get the mix right. We are using digital tools – in India it is called AI – which is very good to screen molecules. Small chemical molecules have 25-50 atoms per molecule. In biological molecules, we are talking about 250,000 atoms per molecule. To screen these complex structures, you need a lot of computing power and digitalisation.
Denne historien er fra January 12, 2020-utgaven av Business Today.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent ? Logg på
Denne historien er fra January 12, 2020-utgaven av Business Today.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent? Logg på
"Moving to cloud helped us grow❞
What was the problem you were grappling with?
She's Got Time
MORE WOMEN ARE BECOMING WATCH CONNOISSEURS, SEEKING OUT BOTH JEWELLED AND TECHNICAL WATCHES FOR THEIR STYLE AND CRAFTSMANSHIP
RISING STAR
PARUL GULATI IS a name that's been steadily gaining prominence in the Indian entertainment industry after she appeared on season 2 of Shark Tank in 2023. She has become a multifaceted personality who effortlessly transitions between acting and entrepreneurship.
Building on a Legacy
WHEN ZAHABIYA KHORAKIWALA stepped into her role as Managing Director of Wockhardt Hospitals over a decade ago, she confronted formidable challenges that have since turned into achievements.
LEADER IN INNOVATION
AS FEDEX'S PRESIDENT (Middle East, Indian subcontinent and Africa), Kami Viswanathan has a lot on her plate.
WAITING IN THE WINGS
Here are those who missed out as they have not yet completed a year in office; they'll be strong contenders in 2025
A DECENT PROPOSAL
IN TODAY'S WORLD OF TRYING TO CREATE AN EQUITABLE SPACE, BOTH MEN AND WOMEN CONTRIBUTE TO THEIR HOUSEHOLDS. WOMEN ARE ENCOURAGED TO HAVE THEIR OWN SAVINGS POOL AND INVESTMENT ROUTINE. GIVEN THIS, HOW SHOULD FUTURE BRIDES APPROACH FINANCIAL PLANNING?
Women and the STEM Bias
EMPOWERING WOMEN IN STEM WILL NOT ONLY BENEFIT INDIVIDUALS, BUT ALSO STRENGTHEN THE ENTIRE INDUSTRY, DRIVING INNOVATION AND PROGRESS.
ROCKET WOMEN
WOMEN IN INDIA ARE NOT ONLY VENTURING INTO SPACE BUT ARE ALSO STARTING TO SPEARHEAD THE COUNTRY'S EFFORTS IN THE GLOBAL SPACE RACE.
ONE STEP FORWARD
THE NUMBER OF WOMEN INDEPENDENT DIRECTORS IS GROWING STEADILY, BUT IT'S A LONG WAY FROM GENDER PARITY. MUCH MORE NEEDS TO BE DONE TO BREAK THE GLASS CEILING IN BOARDROOMS.